Drug Type Monoclonal antibody |
Synonyms XBH 52, XBH-52, XBH52 |
Target |
Action antagonists |
Mechanism KIR3DL2 antagonists(Killer cell immunoglobulin-like receptor 3DL2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Discovery | China | 28 Jun 2023 | |
| Neoplasms | Discovery | China | 28 Jun 2023 |






